Overview

• Biotech firm's Q4 revenue of $0.7 bln beat analyst expectations

• Adjusted loss per share for Q4 beat analyst expectations

• Company announced influenza vaccine filing accepted in EU, Canada, and Australia

Outlook

• Moderna targets up to 10% revenue growth in 2026

• Company expects 2026 revenue split: 50% U.S., 50% international

• Moderna anticipates 2026 R&D expenses of $3.0 bln

Result Drivers

• COVID VACCINE SALES - Q4 revenue driven primarily by COVID vaccine sales, despite a 30% decrease from 2024 due to lower sales volume

• COST REDUCTION - Co reduced operating expenses significantly, surpassing cost-reduction targets by lowering clinical development and manufacturing costs

• GEOGRAPHIC EXPANSION - Strategic focus on geographic expansion and new product launches contributed to growth, with agreements in Mexico and Taiwan

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 19 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Moderna Inc is $31.00, about 22.7% below its February 12 closing price of $40.11

Press Release: ID:nACS54Fhra

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)